

Remarks

Claims 1-17 were pending in the subject application. By this Amendment, the applicants have amended claim 1 and 16 and have cancelled claim 15. Accordingly, claims 1-14, 16 and 17 are pending in the subject application. No new matter has been added by these amendments.

In response to the Election Requirement dated December 13, 2007, the applicants hereby elect Group XII for prosecution at this time. Please note that claim 1 has been amended herein in order for it to correspond to the elected group.

The applicants further elect the following species:

With regard to the first species election, the applicants elect nylidril, wherein R_1 is CH_3 , R_2 is H, R_3 is CH_3 , n is 1, X is CH_2 , and the two benzene rings are each unsubstituted; the full chemical name is 4-hydroxy- α -[1-[(1-methyl-3-phenylpropyl)amino]ethyl]benzenemethanol.

With regard to the second species election, the applicants elect rheumatoid arthritis.

With regard to the third species election, the applicants elect cortisol.

The applicants appreciate that this election of species has been required for the purposes of facilitating the search and expediting prosecution. Accordingly, the applicants respectfully submit that, upon an indication of allowable subject matter, the scope of the claims should not be limited to the elected species.

The Commissioner is hereby authorized to charge any fees under 37 CFR 1.16 or 1.17 as required by this paper to Deposit Account 19-0065.

Respectfully submitted,

A handwritten signature in black ink that reads "David Saliwanchik". The signature is fluid and cursive, with the first name "David" and last name "Saliwanchik" clearly distinguishable.

David R. Saliwanchik
Patent Attorney
Registration No. 31,794
Phone No.: 352-375-8100
Address: P.O. Box 142950
Gainesville, FL 32614-2950

DRS/la